Journal
CANCER LETTERS
Volume 333, Issue 2, Pages 222-228Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.01.036
Keywords
Tumour immunity; Microarray; Prognosis; Biomarker
Categories
Funding
- Lions Cancerforskningsfond
- Swedish Cancer Society
- German Federal Ministry of Education and Research (BMBF)
- German Research Foundation (DFG) [RA 870/5-1, RA 870/4-1]
Ask authors/readers for more resources
A prognostic impact of immunoglobulin kappa C (IGKC) expression has been described in cancer. We analysed the influence of B-cell and plasma cell markers, as well as IGKC expression, in non-small lung cancer (NSCLC) using immunohistochemistry on a tissue microarray. IGKC protein expression was independently associated with longer survival, with particular impact in the adenocarcinoma subgroup. Moreover, a correlation was seen with CD138+ cells, but not with CD20. CD138 expression revealed a comparable association with survival. In conclusion, IGKC expression in stroma-infiltrating plasma cells is a prognostic marker in NSCLC, supporting emerging treatment concepts that exploit the humoral immune response. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
